187 related articles for article (PubMed ID: 38048096)
1. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
[TBL] [Abstract][Full Text] [Related]
5. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
[TBL] [Abstract][Full Text] [Related]
6. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
[TBL] [Abstract][Full Text] [Related]
7. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
[TBL] [Abstract][Full Text] [Related]
8. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
9. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract][Full Text] [Related]
10. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
[TBL] [Abstract][Full Text] [Related]
11. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
VandeVrede L; La Joie R; Thijssen EH; Asken BM; Vento SA; Tsuei T; Baker SL; Cobigo Y; Fonseca C; Heuer HW; Kramer JH; Ljubenkov PA; Rabinovici GD; Rojas JC; Rosen HJ; Staffaroni AM; Boeve BF; Dickerson BC; Grossman M; Huey ED; Irwin DJ; Litvan I; Pantelyat AY; Tartaglia MC; Dage JL; Boxer AL
JAMA Neurol; 2023 May; 80(5):495-505. PubMed ID: 37010841
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Janelidze S; Zetterberg H; Scheffler M; Assal F; Garibotto V; Blennow K; Hansson O; Frisoni GB
J Neurol; 2024 Apr; 271(4):2053-2066. PubMed ID: 38195896
[TBL] [Abstract][Full Text] [Related]
15. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
Barthélemy NR; Salvadó G; Schindler SE; He Y; Janelidze S; Collij LE; Saef B; Henson RL; Chen CD; Gordon BA; Li Y; La Joie R; Benzinger TLS; Morris JC; Mattsson-Carlgren N; Palmqvist S; Ossenkoppele R; Rabinovici GD; Stomrud E; Bateman RJ; Hansson O
Nat Med; 2024 Apr; 30(4):1085-1095. PubMed ID: 38382645
[TBL] [Abstract][Full Text] [Related]
16. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.
Therriault J; Servaes S; Tissot C; Rahmouni N; Ashton NJ; Benedet AL; Karikari TK; Macedo AC; Lussier FZ; Stevenson J; Wang YT; Fernandez-Arias J; Stevenson A; Socualaya KQ; Haeger A; Nazneen T; Aumont É; Hosseini A; Rej S; Vitali P; Triana-Baltzer G; Kolb HC; Soucy JP; Pascoal TA; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
Alzheimers Dement; 2023 Nov; 19(11):4967-4977. PubMed ID: 37078495
[TBL] [Abstract][Full Text] [Related]
17. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
[TBL] [Abstract][Full Text] [Related]
18. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
[TBL] [Abstract][Full Text] [Related]
19. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.
Brum WS; Cullen NC; Janelidze S; Ashton NJ; Zimmer ER; Therriault J; Benedet AL; Rahmouni N; Tissot C; Stevenson J; Servaes S; Triana-Baltzer G; Kolb HC; Palmqvist S; Stomrud E; Rosa-Neto P; Blennow K; Hansson O
Nat Aging; 2023 Sep; 3(9):1079-1090. PubMed ID: 37653254
[TBL] [Abstract][Full Text] [Related]
20. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
